Mild illness at or after measles vaccination does not reduce seroresponse in young children

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 837-843

  Scott, S ^a   Cutts, F T ^a   Nyandu, B ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Ministry of Health   (Democratic Republic Congo)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CONJUNCTIVITIS; COUGHING; DEMOCRATIC REPUBLIC CONGO; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; FEVER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES VACCINATION; PRIORITY JOURNAL; RASH; RHINORRHEA; SEROCONVERSION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, VIRAL; CONJUNCTIVITIS; COUGH; DIARRHEA; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES; MEASLES VACCINE; RHINITIS;

EID: 0033605099     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00268-0     Document Type: Article

References (21)

1. Halsey N.A., Boulos R., Mode F., Andre J., Bowman L., Yaeger R.G.et al. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition and concurrent illnesses. N Engl J Med. 313:1985;544-549.
2. Krober M.S., Stracener C.E., Bass J.W. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. J Am Med Assoc. 265:1991;2095-2096.
3. King G.E., Markowitz L.E., Heath J., Redd S.C., Coleman S., Bellini W.J.et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. J Am Med Assoc. 275:1996;704-707.
4. Ndikuyeze A., Munoz A., Stewart J., Modlin J., Heymann D., Herrmann K.L.et al. Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol. 17:1988;448-455.
5. Simasathien S., Migasena S., Bellini W., Samakoses R., Pitisuttitham P., Bupodom W.et al. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine. 15:1997;329-334.
6. Global Programme for Vaccines and Immunization. Immunization policy. Geneva: WHO/EPI/GEN/95.3, 1995.
7. Hutchins S., Jansen H., Robertson S., Evans P., Kim-Farley R. Studies of missed opportunities for immunization in developing and industrialized countries. Bull World Health Org. 71:1993;549-560.
8. Migasena S., Simasathien S., Samakoses R., Pitisuttitham P., Heath J., Bellini W.et al. Adverse impact of infections on antibody responses to measles vaccination. Vaccine. 16:1998;647-652.
9. Cutts F., Nyandu B., Markowitz L., Forsey T., Zell E., Othepa O.et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of meduim- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine. 12:1994;1311-1316.
10. WHO Expanded programme on immunization. Safety and efficacy of high titre measles vaccine at 6 months of age. Wkly Epidemiol Rec. 66:1991;249-251.
11. Albrecht P., Herrmann K., Burns G.R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods. 3:1981;251-260.
12. Sabin A.B., Arechiga F.A., de Castro F.J., Sever J.L., Madden D.L., Shekarchi I.et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. J Am Med Assoc. 249:1983;2651-2662.
13. Markowitz L.E., Sepulveda J., Diaz-Ortega J.L., Valdespino J.L., Albrecht P., Zell E.R.et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med. 322:1990;580-587.
14. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R.et al. Measles antibody: reevaluation of protective titers. J Infect Diseases. 162:1990;1036-1042.
15. Dennehy P.H., Saracen C.L., Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics. 94:1994;514-516.
16. Ratnam S., Gadag V. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatrics. 127:1995;432-434.
17. Edmonson M.B., Davis J.P., Hopfensperger D.J., Berg J.L., Payton L.A. Measles vaccination during the respiratory virus season and risk of vaccine failure. Pediatrics. 98(5):1996;905-910.
18. Cilla G., Peña B., Marimón J.M., Pérez-Trallero E. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Vaccine. 14:1996;492-494.
19. Schwarz A.J.F. Preliminary tests of a highly attenuated measles vaccine. Am J Diseases Children. 103:1962;216-219.
20. Peltola H., Heinonen O.P. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo controlled trial in twins. The Lancet. i:1986;939-942.
21. Weber M.W., Mulholland E.K., Greenwood B.M. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health. 3:1998;268-280.